Experimental HBV Drugs
Experimental HBV Drugs
AASLD 2017: Treatment that Interferes with Viral Assembly Shows Promise for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Sunday, 17 December 2017 00:00
- Written by Liz Highleyman
JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: RNA Interference Therapy Lowers Viral Biomarker in People with Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Friday, 15 December 2017 00:00
- Written by Liz Highleyman
ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the infection, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.
EASL 2017: Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
A pair of investigational nucleotide analog antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the EASL International Liver Congress last month in Amsterdam. Besifovir is in Phase 3 clinical trials, while tenofovir exalidex is in early development.
AASLD 2017: Immune Modulator Inarigivir Looks Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 13 December 2017 00:00
- Written by Liz Highleyman
Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA, and antigens, and potency was enhanced when followed by tenofovir, according to early results from the ACHIEVE trial presented at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2016: Lonafarnib Lowers Hepatitis Delta Levels with Acceptable Side Effects
- Details
- Category: Experimental HBV Drugs
- Published on Monday, 23 January 2017 00:00
- Written by Liz Highleyman
The hepatitis delta virus (HDV) assembly inhibitor lonafarnib reduces HDV viral load and can be safely boosted with ritonavir to allow for higher and more effective doses with acceptable gastrointestinal side effects, according to study results presented at the recent AASLD Liver Meeting in Boston.
More Articles...
- AASLD 2016: GS-4774 Therapeutic Vaccine Shows Little Efficacy in People with Hepatitis B
- AASLD 2016: Nucleic Acid Polymers Reduce HBsAg Levels and Improve Control of Hepatitis B Virus
- EASL 2016: Core Inhibitor NVR 3-778 Plus Pegylated Interferon Inhibits Hepatitis B Activity
- EASL 2016: Tenofovir Alafenamide Works Well Against Hepatitis B with Less Effect on Bones and Kidneys
Web Design and Development by